Life As Never Before Seen

The answer to reversing blindness derives from an entirely new kind of vision. With a unique gene therapy pioneered by Penn Medicine, we can now replace a missing gene and restore vision. Lighting the way not just for the blind but for the future of medicine itself. Another reason why your life is worth Penn Medicine.

Request more information

First Gene Therapy for Inherited Retinal Disease

Pioneering research at Penn Medicine has led to a first-of-its-kind therapy to treat a genetic disease. This FDA-approved gene therapy reverses blindness in children and adults born with a rare form of inherited retinal disease called Leber congenital amaurosis (LCA). LCA, itself a type of early onset retinitis pigmentosa, affects an estimated one out of every 30,000-81,000 newborns and causes progressive deterioration of the poor vision found in early childhood.

The treatment, developed at the University of Pennsylvania with clinical trials carried out at Children’s Hospital of Philadelphia and the University of Iowa, is the first time gene therapy is used to treat an inherited disease and could lead to treatments of other currently untreatable conditions.

Pioneers in Gene Therapy

The FDA approval for the treatment of inherited retinal disease marks the second groundbreaking advance in gene therapy made at Penn Medicine within the year. We made history in August 2017 when the FDA approved a personalized cell therapy for advanced leukemia, the first-ever for cancer cell and gene therapy.

"This is a really, really, exciting time. This could revolutionize treatments not only for different blinding diseases but also for other genetic and acquired diseases for which we have no treatment." -Jean Bennett, MD, PhD

This latest development in gene therapy is the result of more than two decades of painstaking genetic research by Jean Bennett, MD, PhD, and Albert M. Maguire, M.D., both Professors of Ophthalmology and Co-directors of the Center for Advanced Retinal and Ocular Therapeutics at Penn Medicine. They and their colleagues achieved the FDA approval seventeen years after they restored sight to a blind dog named Lancelot, who had a canine version of LCA.

Dr. Bennett’s and Dr. Maguire’s research not only provides hope for patients with LCA, but for everyone with inherited blindness. There are at least 265 different genes in which mutations can cause blindness; breakthroughs in gene therapy are allowing scientists to develop treatments for diseases that were previously untreatable, giving hope to millions.

In This Section

Frequently Asked Questions

Get answers to commonly asked questions about gene therapy for inherited retinal disease.

What Is Gene Therapy?

Learn how gene therapy is used in the treatment of Leber congenital amaurosis.

Share This Page: